Click Holdings Limited (NASDAQ:CLIK) Sees Large Growth in Short Interest

Click Holdings Limited (NASDAQ:CLIK) was the recipient of a significant increase in short interest during the month of July. As of July 31st, there was short interest totaling 19,660 shares, an increase of 913.9% from the July 15th total of 1,939 shares. Based on an average daily volume of 577,994 shares, the days-to-cover ratio is currently 0.0 days. Approximately 1.7% of the shares of the stock are sold short.

Analysts Set New Price Targets

A number of equities analysts have weighed in on CLIK shares. Wall Street Zen raised Click to a “hold” rating in a research note on Saturday, June 13th. Weiss Ratings reissued a “sell (d)” rating on shares of Click in a research report on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Click currently has a consensus rating of “Sell”.

Institutional Trading of Click

A hedge fund recently bought a new position in Click stock. Renaissance Technologies LLC acquired a new stake in Click Holdings Limited (NASDAQ:CLIK) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 14,200 shares of the company’s stock, valued at approximately $25,000. Renaissance Technologies LLC owned approximately 1.23% of Click as of its most recent filing with the Securities & Exchange Commission.

Click Price Performance

CLIK stock traded up $0.01 during midday trading on Wednesday, hitting $1.46. 3,319 shares of the company’s stock were exchanged, compared to its average volume of 1,350,766. The business has a 50-day simple moving average of $1.53 and a two-hundred day simple moving average of $2.38. Click has a 1-year low of $1.32 and a 1-year high of $14.40.

Click (NASDAQ:CLIK) last posted its earnings results on Monday, May 11th. The company reported $0.10 EPS for the quarter. The company had revenue of $3.79 million during the quarter.

Click Company Profile

Click Therapeutics, Inc (NASDAQ: CLIK) is a clinical-stage digital therapeutics company developing software-based treatments for neurological, psychiatric and chronic diseases. Its platform delivers prescription digital therapies via mobile and web applications, combining evidence-based cognitive behavioral interventions, digital monitoring tools and patient engagement techniques. Click’s approach is designed to complement or extend traditional pharmacological and behavioral treatments for conditions such as major depressive disorder, insomnia and tobacco use disorder.

Founded in 2014, Click has progressed multiple programs through randomized controlled trials and regulatory review.